The Cigna Group

NYSE:CI Voorraadrapport

Marktkapitalisatie: US$74.6b

Cigna Group Toekomstige groei

Future criteriumcontroles 1/6

Cigna Group zal naar verwachting groeien in winst en omzet met respectievelijk 6.8% en 4.2% per jaar. De winst per aandeel zal naar verwachting groeien met 10.6% per jaar. Het rendement op het eigen vermogen zal over 3 jaar naar verwachting 19.1% zijn.

Belangrijke informatie

6.8%

Groei van de winst

10.64%

Groei van de winst per aandeel

Healthcare winstgroei18.3%
Inkomstengroei4.2%
Toekomstig rendement op eigen vermogen19.13%
Dekking van analisten

Good

Laatst bijgewerkt22 May 2026

Recente toekomstige groei-updates

Analyseartikel • May 04

The The Cigna Group (NYSE:CI) First-Quarter Results Are Out And Analysts Have Published New Forecasts

The Cigna Group ( NYSE:CI ) came out with its first-quarter results last week, and we wanted to see how the business is...

Recent updates

Seeking Alpha • May 18

Cigna: Shares Marching To Full Recovery

Summary Cigna Group is reiterated as a "Buy," driven by strong Q1 2026 results, raised guidance, and sustained business momentum. CI’s pharmacy and behavioral health segments are fueling revenue growth, while divestitures and PBM reform temporarily temper 2026 earnings. Shares trade at a 25% discount to a $377 fair value estimate, offering potential 15% annual total returns through 2031. Cigna’s robust balance sheet, market-leading dividend coverage, and growth catalysts in biosimilars and behavioral health underpin the investment thesis. Read the full article on Seeking Alpha
Analyseartikel • May 04

The The Cigna Group (NYSE:CI) First-Quarter Results Are Out And Analysts Have Published New Forecasts

The Cigna Group ( NYSE:CI ) came out with its first-quarter results last week, and we wanted to see how the business is...
Narratiefupdate • May 02

CI: Leadership Transition And Buybacks Will Support Future Share Upside

Analysts have increased their price target on Cigna Group by about $1. This reflects small adjustments to fair value, discount rate, revenue growth, profit margin, and future P/E assumptions in their models.
Narratiefupdate • Apr 17

CI: Leadership Transition And Buybacks Will Drive Future Upside

Analysts have trimmed their average price target on Cigna Group by about $0.38 to roughly $338.42, reflecting small updates to fair value estimates, discount rate, revenue growth, profit margin, and future P/E assumptions. What's in the News The Cigna Group plans a leadership transition, with current CEO David M.
Narratiefupdate • Apr 02

CI: Leadership Transition And Onsite Care Expansion Will Drive Future Upside

Analysts have slightly refined their view on Cigna Group, trimming the price target by a fraction to $338.79 as updated assumptions for revenue growth, profit margins, and future P/E bring the model into closer alignment with their latest expectations. What's in the News Cigna Group plans a leadership transition, with David M.
Narratiefupdate • Mar 19

CI: Onsite Care Expansion And Leadership Transition Will Support Future Upside

Analysts have nudged their fair value estimate for Cigna Group from about $336.67 to roughly $338.80. This reflects updated views on revenue growth, profit margins, and an anticipated forward P/E of around 13.43x.
Narratiefupdate • Mar 05

CI: Onsite Care Expansion Will Support Future Upside Potential

Analysts now set Cigna Group's fair value estimate at about $336.67, up from roughly $332.62, reflecting updated assumptions that incorporate slightly higher revenue growth, profit margins, and a lower future P/E multiple. What's in the News Cigna Group plans a leadership transition, with CEO David M.
Narratiefupdate • Feb 19

CI: Higher Margin Outlook And Onsite Care Expansion Will Support Upside

Analysts have modestly lifted their price target on Cigna Group to $332.62 from $326.92, citing updated assumptions that combine slightly lower revenue growth with a higher profit margin and a future P/E of 15.62. What's in the News A class action lawsuit has been filed against Express Scripts, Cigna, and Evernorth, alleging a rebate diversion scheme that used an offshore entity, Ascent, to collect billions of dollars in kickbacks labeled as fees instead of passing rebates through to pharmacy benefit management clients, including the Plumbers' Welfare Fund.
Narratiefupdate • Feb 04

CI: Onsite Clinic And Stable Assumptions Will Support Future Upside

Analysts have kept their price target for The Cigna Group broadly unchanged at about US$327, citing only slight adjustments to revenue growth, profit margin and future P/E assumptions rather than any major shift in their outlook. What's in the News Hankook Tire America Corp.
Narratiefupdate • Jan 21

CI: Completed Buybacks And New Employee Clinic Will Support Future Upside

Analysts have nudged their fair value estimate for Cigna Group slightly higher to US$326.92 from US$325.57, citing minor refinements to discount rate assumptions, revenue growth expectations, profit margin inputs, and the forward P/E multiple used in their models. What's in the News Hankook Tire America Corp.
Narratiefupdate • Jan 07

CI: Massive Share Buyback And Clinic Expansion Will Support Future Earnings Upside

Analysts have slightly reduced their price target for Cigna Group, trimming fair value by about $0.69 to $325.57 as they factor in a more moderate revenue growth outlook, along with a small improvement in expected profit margins and future P/E assumptions. What's in the News Hankook Tire America Corp.
Narratiefupdate • Dec 15

CI: Massive Share Buyback Will Drive Future Earnings Upside Momentum

Narrative Update on Cigna Group Analysts have slightly lowered their price target on Cigna Group by approximately $2 to around $326 per share, reflecting modest tweaks to assumptions on long term growth, profitability, and valuation multiples, while maintaining a broadly constructive outlook. What's in the News Cigna Group reported that between July 1 and September 30, 2025, it repurchased no additional shares under its existing authorization, having already completed the buyback of about 133.5 million shares, or 41.09% of shares outstanding, for roughly $34.44 billion since the program was announced in December 2018 (company filing).
Narratiefupdate • Nov 30

CI: Massive Share Buyback Will Drive Future Earnings Upside Momentum

Analysts have raised their price target for Cigna Group to $328.35 per share, citing moderate adjustments to key financial metrics. These include a higher projected future price-to-earnings ratio and continued expectations for growth and profitability.
Narratiefupdate • Nov 16

CI: Significant Buybacks And 2026 Guidance Will Drive Upside Momentum

Narrative Update on Cigna Group Analysts have lowered their price target for Cigna Group from $349.04 to $328.35. This change reflects adjustments for a slightly higher discount rate as well as revised expectations for revenue growth and profit margins.
Narratiefupdate • Nov 01

CI: Share Repurchase Momentum Will Drive Long-Term Shareholder Value Creation

Analysts have lowered their price target for Cigna Group from $369.13 to $349.04. This change reflects updated expectations around modestly higher revenue growth, which are offset by a slight dip in profit margin projections.
Analyseartikel • Jul 10

The Cigna Group (NYSE:CI) Screens Well But There Might Be A Catch

When close to half the companies in the United States have price-to-earnings ratios (or "P/E's") above 19x, you may...
Analyseartikel • Jun 19

These 4 Measures Indicate That Cigna Group (NYSE:CI) Is Using Debt Reasonably Well

Some say volatility, rather than debt, is the best way to think about risk as an investor, but Warren Buffett famously...
Seeking Alpha • Mar 31

The Cigna Group: Compelling Exposure To Diversified Healthcare At A Discount Price

Summary Cigna is positioned to benefit from utilization normalization and aims for 10%-14% annual EPS growth by reducing Medicare exposure and improving Commercial business. Despite industry challenges, Cigna achieved 8%-9% YoY EPS growth in 2023-2024, demonstrating strong cost discipline and effective management. The sale of Cigna's Medicare unit and focus on lower-cost biosimilars and streamlined care accessibility are key strategic moves for future growth. With an attractive valuation and minimal downside risk, Cigna stock is rated a BUY, offering at least 33% upside potential even in bearish conditions. Read the full article on Seeking Alpha
Seeking Alpha • Feb 17

Cigna Is A Buy: Market Overreaction Creates A Big Opportunity

Summary Cigna looks undervalued at under 10x earnings, with strong growth potential. Evernorth continues to expand, adding to the company’s long-term value. Large stock buybacks are supporting earnings per share and investor returns. Regulatory risks, rising costs, and competition remain challenges to watch. If Cigna meets its targets, the stock could rise 20-30% from here. Read the full article on Seeking Alpha
Seeking Alpha • Jan 18

Cigna: Buy The Drop On This Undervalued Growth Stock

Summary Cigna's current valuation presents a compelling opportunity, trading at a forward PE of 9.9, significantly below its historical average of 12.0x. The company carries diversified revenue streams and consistent earnings growth, with Healthcare and Evernorth divisions driving strong performance and a 13% EPS CAGR over 10 years. Management targets 10-14% long-term annual EPS growth, supported by increased biosimilar adoption, behavioral health services growth, and aggressive share buybacks. CI's growing dividend and robust fundamentals make it an attractive choice for value and growth investors, despite potential regulatory and macroeconomic risks. Read the full article on Seeking Alpha
Seeking Alpha • Dec 13

Cigna And The Risk Of PBMs - I'm Staying Out Above $230/Share

Summary Cigna faces significant risks due to potential healthcare reforms and scrutiny on PBMs, making it a "Hold" until it drops below $230/share. The US healthcare system's high costs and structural issues contribute to the uncertainty surrounding Cigna's long-term profitability and business model. Despite strong historical performance, the potential breakup of PBMs and legislative changes could drastically impact Cigna's future earnings and growth. The current valuation does not justify investment; Cigna's appeal lies in its fundamental strengths but is overshadowed by systemic risks and political uncertainties. Read the full article on Seeking Alpha
Seeking Alpha • Sep 26

Cigna: This Dividend Grower Could Be Worth Buying Now

Summary The managed care company's total revenue and non-GAAP EPS climbed higher in the second quarter. Cigna's dividend is comfortably covered by non-GAAP EPS and free cash flow. Shares of the stock appear to be priced at a 17% discount to fair value. Cigna could be set up to generate strong total returns in the next couple of years. Read the full article on Seeking Alpha
Seeking Alpha • Sep 19

Cigna: Growth From Specialty Pharmacy And Care; Initiate With 'Buy'

Summary I am initiating a 'Buy' rating for Cigna with a one-year target price of $450 per share, driven by strong Specialty and Cigna Healthcare growth. Cigna's Specialty Pharmacy and Care Market, accounting for 30% of revenue, is poised for above-market growth due to its leadership in the chronic market and biosimilar offerings. Cigna Healthcare's divestiture of low-margin Medicare businesses will allow focus on employer-sponsored plans, targeting small and mid-size enterprises, contributing to 7% organic revenue growth. Despite low operating margins and elevated cost trends, Cigna's share repurchase program and SG&A optimization are expected to support future margin expansion and free cash flow growth. Read the full article on Seeking Alpha
Seeking Alpha • Jul 29

Cigna Group: Services Focus Leads To Outperformance

Summary Cigna Group's medical memberships are focused on "services-only" commercial memberships. The fee-based rather than risk-based nature of these memberships makes Cigna more resilient to rising medical costs. The Evernorth segment should see high-single-digit growth for the foreseeable future, driven by Healthcare Services and specialty pharmacy Accredo. The low valuation coupled with the mid-single-digit earnings growth outlook makes Cigna stock attractive at current prices. Read the full article on Seeking Alpha
Seeking Alpha • Jul 12

Cigna: Game Over For PBMs?

Summary Pharmacy Benefit Managers are increasingly in the spotlight of regulators and the media, potentially leading to government intervention. Express Scripts, Cigna's PBM, is responsible for nearly 75% of the company's revenue, which raises the question of whether CI stock is still a safe investment. This article discusses the potential implications in a scenario-based approach, focusing on segment profit, consolidated profit, dividend safety, and valuation. In addition, I share my thoughts on the recent opioid litigation in Arkansas and explain why I continue to sleep well with my investment in Cigna. Read the full article on Seeking Alpha

Winst- en omzetgroeiprognoses

NYSE:CI - Toekomstschattingen van analisten en financiële gegevens uit het verleden (USD Millions )
DatumInkomstenInkomstenVrije kasstroomGeldmiddelen uit operationele activiteitenGem. Aantal analisten
12/31/2028312,6227,91110,11711,22510
12/31/2027296,9607,72810,10810,39314
12/31/2026284,0046,6229,0399,39314
3/31/2026277,8926,2887,6608,812N/A
12/31/2025274,9005,9578,3899,601N/A
9/30/2025268,0776,1477,4378,664N/A
6/30/2025262,0235,0183,9445,292N/A
3/31/2025255,3685,0346,0107,443N/A
12/31/2024247,1213,4348,95710,363N/A
9/30/2024232,5863,0395,1846,618N/A
6/30/2024217,9403,7087,9609,398N/A
3/31/2024206,0033,62010,16011,625N/A
12/31/2023195,2655,16410,24011,813N/A
9/30/2023189,9045,32810,89212,445N/A
6/30/2023186,1376,67711,41412,902N/A
3/31/2023183,0296,77410,23911,654N/A
12/31/2022180,5186,7047,3618,656N/A
9/30/2022180,4536,6279,57810,832N/A
6/30/2022179,4605,4918,4029,668N/A
3/31/2022177,1135,4016,9288,128N/A
12/31/2021174,0695,3706,0377,191N/A
9/30/2021170,1028,3846,0417,210N/A
6/30/2021166,7698,1514,9155,986N/A
3/31/2021162,9038,4388,4879,556N/A
12/31/2020160,4018,4589,25610,350N/A
9/30/2020156,9345,3007,7648,849N/A
6/30/2020154,5355,2639,33910,415N/A
3/31/2020154,0894,9177,0578,180N/A
12/31/2019153,5665,104N/A9,485N/A
9/30/2019129,6214,271N/A6,818N/A
6/30/2019102,5223,692N/A4,981N/A
3/31/201975,1833,090N/A4,937N/A
12/31/201848,6502,637N/A3,770N/A
9/30/201844,7682,759N/A4,219N/A
6/30/201843,8002,547N/A4,830N/A
3/31/201842,7452,554N/A4,532N/A
12/31/201741,8062,237N/A4,086N/A
9/30/201741,3322,353N/A4,358N/A
6/30/201740,7232,249N/A5,035N/A
3/31/201740,2581,946N/A4,684N/A
12/31/201639,8381,867N/A4,026N/A
9/30/201639,2521,911N/A4,315N/A
6/30/201638,7612,002N/A3,017N/A
3/31/201638,2932,080N/A3,117N/A
12/31/201537,8762,094N/A2,933N/A
9/30/201537,2762,135N/A2,319N/A
6/30/201536,6442,122N/A2,175N/A

Toekomstige groeivoorspellingen analisten

Verdiensten versus spaarpercentage: De verwachte winstgroei CI ( 6.8% per jaar) ligt boven de spaarquote ( 3.5% ).

Winst versus markt: De winst van CI ( 6.8% per jaar) zal naar verwachting langzamer groeien dan de markt US ( 16.7% per jaar).

Hoge groeiwinsten: De winst van CI zal naar verwachting groeien, maar niet aanzienlijk.

Omzet versus markt: De omzet van CI ( 4.2% per jaar) zal naar verwachting langzamer groeien dan de markt US ( 11.7% per jaar).

Hoge groei-inkomsten: De omzet van CI ( 4.2% per jaar) zal naar verwachting langzamer groeien dan 20% per jaar.

Groeiprognoses winst per aandeel

Toekomstig rendement op eigen vermogen

Toekomstige ROE: Het rendement op eigen vermogen CI zal naar verwachting over 3 jaar laag zijn ( 19.1 %).

Ontdek groeibedrijven

7D

1Y

7D

1Y

7D

1Y

Bedrijfsanalyse en status van financiële gegevens

GegevensLaatst bijgewerkt (UTC-tijd)
Bedrijfsanalyse2026/05/22 01:18
Aandelenkoers aan het einde van de dag2026/05/22 00:00
Inkomsten2026/03/31
Jaarlijkse inkomsten2025/12/31

Gegevensbronnen

De gegevens die gebruikt zijn in onze bedrijfsanalyse zijn afkomstig van S&P Global Market Intelligence LLC. De volgende gegevens worden gebruikt in ons analysemodel om dit rapport te genereren. De gegevens zijn genormaliseerd, waardoor er een vertraging kan optreden voordat de bron beschikbaar is.

PakketGegevensTijdframeVoorbeeld Amerikaanse bron *
Financiële gegevens bedrijf10 jaar
  • Resultatenrekening
  • Kasstroomoverzicht
  • Balans
Consensus schattingen analisten+3 jaar
  • Financiële prognoses
  • Koersdoelen analisten
Marktprijzen30 jaar
  • Aandelenprijzen
  • Dividenden, splitsingen en acties
Eigendom10 jaar
  • Top aandeelhouders
  • Handel met voorkennis
Beheer10 jaar
  • Leiderschapsteam
  • Raad van bestuur
Belangrijkste ontwikkelingen10 jaar
  • Bedrijfsaankondigingen

* Voorbeeld voor effecten uit de VS, voor niet-Amerikaanse effecten worden gelijkwaardige formulieren en bronnen gebruikt.

Tenzij anders vermeld zijn alle financiële gegevens gebaseerd op een jaarperiode, maar worden ze elk kwartaal bijgewerkt. Dit staat bekend als Trailing Twelve Month (TTM) of Last Twelve Month (LTM) gegevens. Meer informatie.

Analysemodel en Snowflake

Details van het analysemodel dat is gebruikt om dit rapport te genereren zijn beschikbaar op onze Github-pagina. We hebben ook handleidingen over hoe je onze rapporten kunt gebruiken en tutorials op YouTube.

Leer meer over het team van wereldklasse dat het Simply Wall St-analysemodel heeft ontworpen en gebouwd.

Industrie en sector

Onze industrie- en sectormetrics worden elke 6 uur berekend door Simply Wall St, details van ons proces zijn beschikbaar op Github.

Bronnen van analisten

The Cigna Group wordt gevolgd door 40 analisten. 17 van deze analisten hebben de schattingen van de omzet of winst ingediend die zijn gebruikt als input voor ons rapport. Inzendingen van analisten worden de hele dag door bijgewerkt.

AnalistInstelling
null nullArgus Research Company
Hua HaBaird
Andrew MokBarclays